From Pulse 2.0 · Amit Chowdhry · · 1m 40s
Marrow Therapeutics Launches With $173 Million
Marrow Therapeutics secures $173 million for bone marrow-targeted medicines to treat blood disorders.
In brief
Marrow Therapeutics secures $173 million for bone marrow-targeted medicines to treat blood disorders. Marrow Therapeutics received $173 million in funding to develop genetic medicines for severe blood and bone marrow disorders. Originally reported by Pulse 2.0.
Funding Announcement
Marrow Therapeutics has launched with $173 million in combined Series A and Series B funding to develop genetic medicines for severe blood and bone marrow disorders.
Funding Breakdown
The $53 million Series A round was co-led by Scion Life Sciences and venBio, with OrbiMed leading a subsequent $120 million Series B financing.
Investors
All Series A investors participated in the Series B alongside RTW Investments, Surveyor Capital, Opaleye, NEXTBio Capital, Affinity Advisors, KKR, Spruce Street Capital, and Columbia Threadneedle Investments.
Company Background
Scion Life Sciences founded Marrow Therapeutics, which is headquartered in Watertown, Massachusetts.
Bone Marrow-Targeting Platform
Marrow is developing engineered antibodies that target the transferrin receptor, also known as TfR1, in bone marrow.
Platform Purpose
The company’s Transferrin Antibody Bioconjugate platform delivers therapeutic payloads directly to bone marrow cells for multiple hematologic and bone marrow diseases.
Lead Program Targets Two Blood Disorders
Marrow’s lead candidate, MAR-101, is being developed for sickle cell disease and beta thalassemia through studies to support an investigational new drug application.
Therapeutic Strategy
MAR-101 decreases BCL11A and reactivates fetal hemoglobin production to treat sickle cell disease and beta thalassemia.
Pipeline in a Product
Marrow uses a single therapeutic approach for both conditions, calling it a 'pipeline in a product' strategy to validate the platform across multiple diseases.
The headline
Marrow Therapeutics received $173 million in funding to develop genetic medicines for severe blood and bone marrow disorders.
Read the TL;DR — this story on one card.

